Cargando…
Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells
Programmed death ligand–1 (PD–L1) is one of the immune checkpoint molecule localized on the plasma membrane of numerous cancer cells that negatively regulates T-cell-mediated immunosurveillance. Despite the remarkable efficacy and safety profile of immune checkpoint inhibitors (ICIs), such as anti-P...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100183/ https://www.ncbi.nlm.nih.gov/pubmed/35566582 http://dx.doi.org/10.3390/jcm11092457 |
_version_ | 1784706790844268544 |
---|---|
author | Tameishi, Mayuka Ishikawa, Honami Tanaka, Chihiro Kobori, Takuro Urashima, Yoko Ito, Takuya Obata, Tokio |
author_facet | Tameishi, Mayuka Ishikawa, Honami Tanaka, Chihiro Kobori, Takuro Urashima, Yoko Ito, Takuya Obata, Tokio |
author_sort | Tameishi, Mayuka |
collection | PubMed |
description | Programmed death ligand–1 (PD–L1) is one of the immune checkpoint molecule localized on the plasma membrane of numerous cancer cells that negatively regulates T-cell-mediated immunosurveillance. Despite the remarkable efficacy and safety profile of immune checkpoint inhibitors (ICIs), such as anti-PD–L1 antibodies, restricted poor therapeutic responses to ICIs are often observed in patients with ovarian cancer. Because higher expression of PD–L1 in advanced ovarian cancer is associated with a decreased survival rate, identifying the potential molecules to regulate the plasma membrane expression of PD–L1 may provide a novel therapeutic strategy to improve the efficacy of ICIs against ovarian cancers. Here, we reveal the involvement of the ezrin/radixin/moesin (ERM) family, which crosslinks transmembrane proteins with the actin cytoskeleton by serving as a scaffold protein, in the plasma membrane expression of PD–L1 in the human epithelial ovarian cancer cell line A2780. Our results demonstrate that PD–L1 and all three ERMs were expressed at the mRNA and protein levels in A2780 cells, and that PD–L1 was highly colocalized with ezrin and moesin, but moderately with radixin, in the plasma membrane. Interestingly, RNA interference-mediated gene silencing of ezrin, but not of radixin or moesin, substantially reduced the plasma membrane expression of PD–L1 without altering its mRNA expression. In conclusion, our results indicate that ezrin may be responsible for the plasma membrane expression of PD–L1, possibly by serving as a scaffold protein in A2780 cells. Ezrin is a potential therapeutic target for improving the efficacy of ICIs against ovarian cancers. |
format | Online Article Text |
id | pubmed-9100183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91001832022-05-14 Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells Tameishi, Mayuka Ishikawa, Honami Tanaka, Chihiro Kobori, Takuro Urashima, Yoko Ito, Takuya Obata, Tokio J Clin Med Article Programmed death ligand–1 (PD–L1) is one of the immune checkpoint molecule localized on the plasma membrane of numerous cancer cells that negatively regulates T-cell-mediated immunosurveillance. Despite the remarkable efficacy and safety profile of immune checkpoint inhibitors (ICIs), such as anti-PD–L1 antibodies, restricted poor therapeutic responses to ICIs are often observed in patients with ovarian cancer. Because higher expression of PD–L1 in advanced ovarian cancer is associated with a decreased survival rate, identifying the potential molecules to regulate the plasma membrane expression of PD–L1 may provide a novel therapeutic strategy to improve the efficacy of ICIs against ovarian cancers. Here, we reveal the involvement of the ezrin/radixin/moesin (ERM) family, which crosslinks transmembrane proteins with the actin cytoskeleton by serving as a scaffold protein, in the plasma membrane expression of PD–L1 in the human epithelial ovarian cancer cell line A2780. Our results demonstrate that PD–L1 and all three ERMs were expressed at the mRNA and protein levels in A2780 cells, and that PD–L1 was highly colocalized with ezrin and moesin, but moderately with radixin, in the plasma membrane. Interestingly, RNA interference-mediated gene silencing of ezrin, but not of radixin or moesin, substantially reduced the plasma membrane expression of PD–L1 without altering its mRNA expression. In conclusion, our results indicate that ezrin may be responsible for the plasma membrane expression of PD–L1, possibly by serving as a scaffold protein in A2780 cells. Ezrin is a potential therapeutic target for improving the efficacy of ICIs against ovarian cancers. MDPI 2022-04-27 /pmc/articles/PMC9100183/ /pubmed/35566582 http://dx.doi.org/10.3390/jcm11092457 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tameishi, Mayuka Ishikawa, Honami Tanaka, Chihiro Kobori, Takuro Urashima, Yoko Ito, Takuya Obata, Tokio Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title | Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title_full | Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title_fullStr | Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title_full_unstemmed | Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title_short | Ezrin Contributes to the Plasma Membrane Expression of PD–L1 in A2780 Cells |
title_sort | ezrin contributes to the plasma membrane expression of pd–l1 in a2780 cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100183/ https://www.ncbi.nlm.nih.gov/pubmed/35566582 http://dx.doi.org/10.3390/jcm11092457 |
work_keys_str_mv | AT tameishimayuka ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT ishikawahonami ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT tanakachihiro ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT koboritakuro ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT urashimayoko ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT itotakuya ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells AT obatatokio ezrincontributestotheplasmamembraneexpressionofpdl1ina2780cells |